MedTrace Logo

Masitinib in Combination With Methotrexate, in Treatment of Patients With Active Rheumatoid Arthritis

NCT00913432 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2018-12-13

No results posted yet for this study

Summary

A 12-week with possible extension, phase II study to compare efficacy and safety of masitinib at 3 and 6 mg/kg/day in combination with methotrexate, in treatment of patients with active rheumatoid arthritis refractory to standard treatments.

Conditions

Interventions

DRUG

masitinib

3 mg/kg/day oral route

DRUG

masitinib

masitinib 6 mg/kg/day oral route

Sponsors & Collaborators

  • AB Science

    lead INDUSTRY

Principal Investigators

  • Jacques Tebib, MD, PhD · CHU de Lyon Sud

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2009-06-30
Completion
2010-09-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00913432 on ClinicalTrials.gov